Combunox's Future At Forest May Depend On Success Of New Trial Program
This article was originally published in The Pink Sheet Daily
Executive Summary
The future of Forest's combination pain therapy Combunox (oxycodone/ibuprofen)could depend on the success of a new product trial program launched in late September, the company suggested
You may also be interested in...
Forest Cuts Combunox Detailing Following Disappointing Launch
Forest plans to reassign the combination pain therapy’s 1,100-person sales force to detail Lexapro, Namenda and the launch of nebivolol, pending FDA approval.
Forest Cuts Combunox Detailing Following Disappointing Launch
Forest plans to reassign the combination pain therapy’s 1,100-person sales force to detail Lexapro, Namenda and the launch of nebivolol, pending FDA approval.
Forest To Use New Data To Promote Lexapro In Face Of Paxil CR Relaunch
Lexapro market share gain is behind expectations because of the market reentry of GlaxoSmithKline’s Paxil CR, increased detailing by antidepressant competitors and more aggressive promotion of generics by payors.